Segment Information

12 Months Ended

Dec. 31, 2012

Segment Reporting [Abstract]

Segment Information

NOTE 14 – SEGMENT INFORMATION

Information related to the Company’s reportable operating business segments is shown below. The Company’s reportable segments are reported in a manner consistent with the way management evaluates the businesses. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies. The Company has identified the following business segments:

· Nuclear Medicine segment consists of the manufacturing of sources and standards associated with SPECT (Single Photon Emission Computed Tomography) imaging, patient positioning, and calibration or operational testing of dose measuring equipment for nuclear pharmacy and in 2012 and 2011 includes consolidated reporting of the Company’s 50/50 joint venture, TI Services, LLC.

· Cobalt Products segment includes the production of high and medium specific activity bulk cobalt, recycling expended cobalt sources, and fabrication of a wide array of cobalt teletherapy and experimental irradiator source capsules.

· Radiochemical Products segment includes production of various isotopically pure radiochemicals for medical, industrial, or research applications. These products are either directly produced by the company or are purchased in bulk from other producers and distributed by the Company in customized packages and chemical forms tailored to customer and market demands. Iodine-131 is the most predominant radiochemical sold in this segment.

· Fluorine Products segment concerns the production of small scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility. The Company has developed or acquired all patent rights to these processes.

· Radiological Services segment concerns a wide array of miscellaneous services such as processing of gemstone which has undergone irradiation for color enhancement, radiological engineering consultant services, Type A package certification testing, and waste packaging/recycle services.

· Transportation segment includes transportation services the Company engages in for the commercial transfer of nuclear products for which the Company is licenses to transport.

The following presents certain segment information as of and for the years ended December 31, 2012 and 2011:

Sale of product	2012		2011
Radiochemical products	$	1,677,291	$	1,811,935
Cobalt products		1,369,130		2,339,154
Nuclear medicine standards		4,169,710		4,795,369
Radiological services		177,871		228,631
Fluorine products		-		-
Transportation		227,932		286,923
Total segments		7,621,934		9,462,012
Corporate revenue		-		-
Total consolidated	$	7,621,934	$	9,462,012

Depreciation and amortization	2012		2011
Radiochemical products	$	37,173	$	36,615
Cobalt products		94,957		105,113
Nuclear medicine standards		21,439		16,936
Radiological services		10,399		10,399
Fluorine products		232,113		205,459
Transportation		13,374		13,807
Total segments		409,455		388,329
Corporate revenue		5,726		4,663
Total consolidated	$	415,181	$	392,992

Segment income (loss)	2012		2011
Radiochemical products	$	94,165	$	141,324
Cobalt products		401,132		1,055,662
Nuclear medicine standards		581,342		674,377
Radiological services		90,102		130,785
Fluorine products		(1,050,995)		(4,428,799)
Transportation		(15,734)		13,911
Total segments		100,012		(2,412,740)
Corporate loss		(2,340,822)		(3,537,698)
Net loss	$	(2,240,810)	$	(5,950,438)

Expenditures for segment assets	2012		2011
Radiochemical products	$	2,793	$	-
Cobalt products		31,742		3,193
Nuclear medicine standards		4,429		86,149
Radiological services		255,000		-
Fluorine products		1,537,935		3,439,365
Transportation		-		-
Total segments		1,831,899		3,528,707
Corporate purchases		3,414		-
Total consolidated	$	1,835,313	$	3,528,707

Segment assets	2012		2011
Radiochemical products	$	229,516	$	196,065
Cobalt products		1,510,183		1,586,748
Nuclear medicine standards		451,252		1,019,239
Radiological services		267,414		19,646
Fluorine products		6,239,235		4,922,409
Transportation		29,734		39,112
Total segments		8,727,334		7,783,219
Corporate assets		3,314,571		4,147,586
Total consolidated	$	12,041,905	$	11,930,805